Literature DB >> 32016611

Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines.

Samarwadee Plianwong1,2, Bindu Thapa3, Remant Bahadur Kc1, Cezary Kucharski1, Theerasak Rojanarata2, Hasan Uludağ4,5,6,7.   

Abstract

PURPOSE: Short interfering RNA (siRNA) therapy promises a new era in treatment of breast cancers but effective delivery systems are needed for clinical use. Since silencing complementary targets may offer improved efficacy, this study was undertaken to identify non-viral carriers for combinatorial siRNA delivery for more effective therapy.
METHODS: A library of lipid-substituted polymers from low molecular weight polyethyleneimine (PEI), linoleic acid (LA) and α-linoleic acid (αLA) with amide or thioester linkages was prepared and investigated for delivering Mcl-1, survivin and STAT5A siRNAs in breast cancer cells.
RESULTS: The effective polymers formed 80-190 nm particles with similar zeta-potentials, but the serum stability was greater for complexes formed with amide-linked lipid conjugates. The LA and αLA substitutions, with the low molecular weight PEI (1.2 kDa and 2.0 kDa) were able to deliver siRNA effectively to cells and retarded the growth of breast cancer cells. The amide-linked lipid substituents showed higher cellular delivery of siRNA as compared to thioester linkages. Upon combinational delivery of siRNAs, growth of MCF-7 cells was inhibited to a greater extent with 2.0PEI-LA9 mediated delivery of Mcl-1 combined survivin siRNAs as compared to individual siRNAs. The qRT-PCR analysis confirmed the decrease in mRNA levels of target genes with specific siRNAs and 2.0PEI-LA9 was the most effective polymer for delivering siRNAs (either single or in combination).
CONCLUSIONS: This study yielded effective siRNA carriers for combinational delivery of siRNAs. Careful choice of siRNA combinations will be critical since targeting individual genes might alter the expression of other critical mediators.

Entities:  

Keywords:  anti-apoptotic proteins; breast cancer; linoleic acid; lipopolymers; non-viral delivery; siRNA delivery

Year:  2020        PMID: 32016611     DOI: 10.1007/s11095-020-2770-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  53 in total

1.  Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line.

Authors:  Hamidreza Montazeri Aliabadi; Breanne Landry; Parvin Mahdipoor; Hasan Uludağ
Journal:  Mol Pharm       Date:  2011-08-23       Impact factor: 4.939

2.  Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy.

Authors:  Hamidreza Montazeri Aliabadi; Robert Maranchuk; Cezary Kucharski; Parvin Mahdipoor; Judith Hugh; Hasan Uludağ
Journal:  J Control Release       Date:  2013-08-30       Impact factor: 9.776

Review 3.  Survivin as a target for new anticancer interventions.

Authors:  Nadia Zaffaroni; Marzia Pennati; Maria Grazia Daidone
Journal:  J Cell Mol Med       Date:  2005 Apr-Jun       Impact factor: 5.310

Review 4.  Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.

Authors:  Alain C Mita; Monica M Mita; Steffan T Nawrocki; Francis J Giles
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

5.  MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.

Authors:  K M Kozopas; T Yang; H L Buchan; P Zhou; R W Craig
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

6.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

Review 7.  siRNA-based approaches in cancer therapy.

Authors:  G R Devi
Journal:  Cancer Gene Ther       Date:  2006-01-20       Impact factor: 5.987

Review 8.  Survivin, versatile modulation of cell division and apoptosis in cancer.

Authors:  Dario C Altieri
Journal:  Oncogene       Date:  2003-11-24       Impact factor: 9.867

9.  Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro.

Authors:  Amy C Richards Grayson; Anne M Doody; David Putnam
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.580

10.  Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines.

Authors:  Manoj B Parmar; Hamidreza Montazeri Aliabadi; Parvin Mahdipoor; Cezary Kucharski; Robert Maranchuk; Judith C Hugh; Hasan Uludağ
Journal:  Front Bioeng Biotechnol       Date:  2015-02-16
View more
  2 in total

1.  Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes.

Authors:  Tinnabhop Santadkha; Wanwisa Skolpap; Remant K C; Aysha Ansari; Cezary Kucharski; Teo Atz Dick; Hasan Uludağ
Journal:  Invest New Drugs       Date:  2022-07-14       Impact factor: 3.651

2.  Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL).

Authors:  Mahsa Mohseni; Cezary Kucharski; Remant Bahadur K C; Mohammad Nasrullah; Xiaoyan Jiang; Hasan Uludağ; Joseph Brandwein
Journal:  PLoS One       Date:  2021-06-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.